

17th April, 2025

- | | |
|--|---|
| <p>(1) BSE Ltd
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001</p> <p>Scrip Code: 500087</p> | <p>(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051</p> <p>Scrip Code: CIPLA</p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg</p> | |

Dear Sir / Madam,

Subject: Update on USFDA inspection at manufacturing facility of Medispray in Kundaim, Goa, India

Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and further to our intimation dated 20th January, 2025, regarding the United States Food and Drug Administration (USFDA) inspection at the manufacturing facility of Medispray Laboratories Private Limited, a wholly-owned subsidiary of the Company ('Medispray') located in Kundaim, Goa, between 14th – 20th January, 2025, we hereby notify that the USFDA, via email communication dated 11th April, 2025 (received by Medispray), has classified the above-referred inspection as Voluntary Action Indicated (VAI).

The Company received this communication on 17th April, 2025 and the disclosure is made within 24 hours. The information is not material and is being made as part of good governance practice.

Please take the above information on record.

Thanking you,

Yours faithfully,
For Cipla Limited

Rajendra Chopra
Company Secretary

Prepared by: Mandar Kurghode